From: Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients
 |  | Objective | Group A | Group B | Group C |
---|---|---|---|---|---|
PTV high dose | Volume [cm3] |  | 142 ± 119 | 93 ± 68 | 144 ± 54 |
 | Mean [%] | 100% | 100.2 ± 0.8 | 100.5 ± 1.0 | 100.0 ± 0.2 |
 | D2% [%] | < 107% | 104.1 ± 2.0 | 104.0 ± 2.2 | 104.4 ± 1.7 |
 | D5-95% [%] | Minimise | 7.2 ± 2.0 | 7.0 ± 3.4 | 7.7 ± 2.7 |
 | D98% [%] | > 95% | 94.6 ± 1.5 | 91.9 ± 6.5 | 93.6 ± 2.2 |
 | V95% [%] | 100 | 97.2 ± 2.0 | 98.9 ± 1.7 | 96.5 ± 2.4 |
 | V107% [%] | 0 | 0.7 ± 3.2 | 0.1 ± 0.2 | 0.4 ± 0.6 |
 | CI95% | 1 | 1.21 ± 0.15 | 1.48 ± 0.43 | 1.06 ± 0.06 |
CTV high dose | Volume [cm3] |  | 82 ± 43 | 59 ± 46 | 103 ± 41 |
 | Mean [%] | 100% | 100.9 ± 0.6 | 101.2 ± 1.3 | 100.6 ± 0.4 |
 | D2% [%] | < 107% | 104.0 ± 1.2 | 104.0 ± 2.1 | 104.4 ± 1.8 |
 | D5-95% [%] | Minimise | 4.6 ± 1.6 | 4.1 ± 1.8 | 5.6 ± 2.1 |
 | D98% [%] | > 95% | 97.8 ± 1.1 | 98.3 ± 1.6 | 96.6 ± 2.0 |
 | V95% [%] | 100 | 99.7 ± 0.7 | 99.6 ± 0.4 | 99.2 ± 1.1 |
 | V107% [%] | 0 | 0.2 ± 0.5 | 0.1 ± 0.1 | 0.4 ± 0.6 |
PTV low dose | Volume [cm3] |  | 253 ± 139 | 384 ± 282 |  |
 | D98% [%] | > 95% | 95.1 ± 2.4 | 94.2 ± 2.6 |  |
 | V95% [%] | 100 | 97.1 ± 5.0 | 97.8 ± 1.1 |  |
 | CI95% | 1 | 1.38 ± 0.16 | 1.55 ± 0.20 |  |
CTV low dose | Volume [cm3] |  | 184 ± 105 | 264 ± 178 |  |
 | D98% [%] | > 95% | 100.7 ± 2.8 | 99.8 ± 2.1 |  |
 | V95% [%] | 100 | 99.0 ± 4.0 | 99.7 ± 0.3 |  |